Yanan Zhu
Stock Analyst at Wells Fargo
(4.12)
# 465
Out of 5,162 analysts
83
Total ratings
42.31%
Success rate
18.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanan Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Overweight | $15 → $60 | $15.53 | +286.35% | 7 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Equal-Weight | $12 → $15 | $12.76 | +17.55% | 8 | Mar 3, 2026 | |
| SRPT Sarepta Therapeutics | Maintains: Overweight | $45 → $38 | $16.40 | +131.71% | 8 | Feb 27, 2026 | |
| ACLX Arcellx | Downgrades: Equal-Weight | $115 | $114.39 | +0.53% | 1 | Feb 23, 2026 | |
| SYRE Spyre Therapeutics | Maintains: Overweight | $40 → $50 | $39.89 | +25.34% | 3 | Feb 20, 2026 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $8 → $11 | $4.49 | +144.99% | 4 | Jan 5, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $82 → $100 | $71.19 | +40.47% | 4 | Jan 5, 2026 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Overweight | $42 → $20 | $6.68 | +199.40% | 9 | Oct 23, 2025 | |
| EDIT Editas Medicine | Maintains: Equal-Weight | $3 → $4 | $2.44 | +63.93% | 7 | Sep 3, 2025 | |
| NAMS NewAmsterdam Pharma Company | Initiates: Overweight | $45 | $28.62 | +57.23% | 1 | Aug 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $1.46 | +721.92% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2.5 | $1.17 | +113.68% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $1.44 | +247.22% | 4 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $14 | $3.96 | +253.54% | 5 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $25.16 | +178.22% | 3 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $10 | $4.46 | +124.47% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $65 | $48.75 | +33.33% | 1 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $7.16 | +318.99% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $0.38 | +957.64% | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $3.30 | +13,536.36% | 1 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $272 → $326 | $700.45 | -53.46% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $70 | $10.16 | +588.98% | 2 | Oct 29, 2020 |
uniQure
Mar 9, 2026
Upgrades: Overweight
Price Target: $15 → $60
Current: $15.53
Upside: +286.35%
Intellia Therapeutics
Mar 3, 2026
Maintains: Equal-Weight
Price Target: $12 → $15
Current: $12.76
Upside: +17.55%
Sarepta Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $45 → $38
Current: $16.40
Upside: +131.71%
Arcellx
Feb 23, 2026
Downgrades: Equal-Weight
Price Target: $115
Current: $114.39
Upside: +0.53%
Spyre Therapeutics
Feb 20, 2026
Maintains: Overweight
Price Target: $40 → $50
Current: $39.89
Upside: +25.34%
Taysha Gene Therapies
Jan 5, 2026
Maintains: Overweight
Price Target: $8 → $11
Current: $4.49
Upside: +144.99%
Ionis Pharmaceuticals
Jan 5, 2026
Maintains: Overweight
Price Target: $82 → $100
Current: $71.19
Upside: +40.47%
Arcturus Therapeutics Holdings
Oct 23, 2025
Maintains: Overweight
Price Target: $42 → $20
Current: $6.68
Upside: +199.40%
Editas Medicine
Sep 3, 2025
Maintains: Equal-Weight
Price Target: $3 → $4
Current: $2.44
Upside: +63.93%
NewAmsterdam Pharma Company
Aug 25, 2025
Initiates: Overweight
Price Target: $45
Current: $28.62
Upside: +57.23%
Aug 14, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $1.46
Upside: +721.92%
Aug 13, 2025
Maintains: Equal-Weight
Price Target: $4 → $2.5
Current: $1.17
Upside: +113.68%
Aug 13, 2025
Maintains: Overweight
Price Target: $6 → $5
Current: $1.44
Upside: +247.22%
Aug 8, 2025
Maintains: Overweight
Price Target: $18 → $14
Current: $3.96
Upside: +253.54%
May 7, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $25.16
Upside: +178.22%
Mar 12, 2025
Maintains: Overweight
Price Target: $12 → $10
Current: $4.46
Upside: +124.47%
May 9, 2024
Maintains: Equal-Weight
Price Target: $70 → $65
Current: $48.75
Upside: +33.33%
Apr 22, 2024
Initiates: Overweight
Price Target: $30
Current: $7.16
Upside: +318.99%
Aug 10, 2023
Maintains: Overweight
Price Target: $5 → $4
Current: $0.38
Upside: +957.64%
Mar 27, 2023
Assumes: Overweight
Price Target: $450
Current: $3.30
Upside: +13,536.36%
Feb 2, 2021
Maintains: Equal-Weight
Price Target: $272 → $326
Current: $700.45
Upside: -53.46%
Oct 29, 2020
Maintains: Overweight
Price Target: $79 → $70
Current: $10.16
Upside: +588.98%